RxSight, Inc.
HealthcareNASDAQ:RXST · NASDAQ Global Market
-$0.09 today
Vol 1.00M · Avg 0.75M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-14.1%
avg -30.6%
ROIC
-16.8%
avg -31.4%
ROA
-12.5%
avg 3.5%
Analysis
ROA is currently the strongest return metric at -12.5% versus its period average of 3.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Eric J. Weinberg | Chief Business Development Officer | $2.75M | — | 65 | $32,218.00 | 0.08% |
Mark Wilterding | Chief Financial Officer | $877,380.00 | — | 48 | $12,373.00 | 0.03% |
Ronald Kurtz | President, Chief Executive Officer & Director | $834,131.00 | — | 63 | $80,545.00 | 0.19% |
Ilya Goldshleger | Chief Operating Officer | $634,007.00 | — | 51 | $5.00 | <0.01% |
Scott Gaines | Chief Customer Officer | $472,053.00 | — | 57 | $17,428.00 | 0.04% |
Patrick Cullen | Executive Vice President of Quality & Infrastructure Operations | — | — | — | — | — |
Maureen O'Connell | Executive Vice President of Clinical & Regulatory Affairs | — | — | — | — | — |
Oliver Moravcevic | Vice President of Investor Relations | — | — | — | — | — |
Adam Dashe | Executive Vice President of International | — | — | — | — | — |
Jim Schindler | Executive VP & General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +82.4% | +11.7% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +82.4% over three years. Forward estimates point to Revenue at +11.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Butterfly Network, Inc.
NYSE:BFLY
$1.45B
Surmodics, Inc.
SRDX
$614.51M
Tactile Systems Technology, Inc.
NASDAQ:TCMD
$593.46M
NeuroPace, Inc.
NASDAQ:NPCE
$533.23M
Cerus Corporation
NASDAQ:CERS
$512.94M
OrthoPediatrics Corp.
NASDAQ:KIDS
$457.71M
Delcath Systems, Inc.
NASDAQ:DCTH
$404.59M
Semler Scientific, Inc.
SMLR
$310.75M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$304.44M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$263.38M
Who manages RXST?
RxSight, Inc. (RXST) lists 10 active executives. The top listed executive is Ilya Goldshleger, Chief Operating Officer.
Are RXST insiders buying or selling?
Recent insider activity shows net buying of $39.51M.
Explore More
Continue the stock analysis
Jump to another research area for this company.